Home › Leucemia linfatica cronica › Tennessee › Nashville
Studi clinici su Leucemia linfatica cronica a Nashville, TN
13 studi su Leucemia linfatica cronica cercano partecipanti presso sedi a Nashville e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
In reclutamentoFase 3
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In reclutamentoFase 3
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
In reclutamentoFase 3
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
In reclutamentoFase 2
- SCRI Oncology Partners, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
In reclutamentoFase 3
- SCRI Oncology Partners, Nashville
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
In reclutamentoFase 1/2
- SCRI Oncology Partners, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
In reclutamentoFase 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
In reclutamentoFase 1/2
- TriStar BMT, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- Tennessee Oncology, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
In reclutamentoFase 4
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
In reclutamentoFase 4
- Tennessee Oncology, Nashville
HPC Offered for PRESERVE Expansion
In reclutamentoStudio osservazionale
- Tristar Centennial Medical Center, Nashville
Studi su Leucemia linfatica cronica in altre città
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN18 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
Altri studi a Nashville
- Cancro del polmone non a piccole cellule97 studi
- Cancro al seno81 studi
- Cancro metastatico70 studi
- Cancro colorettale69 studi
- Cancro (tutti i tipi)65 studi
- Cancro ovarico49 studi
- Cancro alla prostata43 studi
- Cancro ai polmoni40 studi
- Carcinoma a cellule squamose della testa e del collo39 studi
- Cancro pancreatico39 studi
- Cancro dell'endometrio38 studi
- Melanoma33 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.